MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

Journal of Alzheimer's Disease

Volumn 26, Issue SUPPL. 3, 2011, Pages 331-336

  Ashford, J W ^a   Adamson, M ^a   Beale, T ^a   La, D ^a   Hernandez, B ^a   Noda, A ^a   Rosen, A ^a,b   OHara, R ^a,b   Fairchild, J K ^a,b   Spielman, D ^a   Yesavage, J A ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; cognition; creatine; dementia; magnetic resonance spectroscopy; memantine; N acetylaspartate

Indexed keywords

CREATINE; MEMANTINE; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXCITOTOXICITY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARIETAL CORTEX; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 80055053970     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-0021     Document Type: Article

References (16)

1. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287-293.
2. Ernst T, Chang L, Melchor R, Mehringer CM (1997) Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203, 829-836. (Pubitemid 27227438)
3. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, OBrien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr (2004) 1H MRspectroscopy incommon dementias. Neurology 63, 1393-1398.
4. Kantarci K (2007) 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80 Spec No 2, S146-S152
5. Kantarci K, Petersen RC, Przybelski SA,Weigand SD, Shiung MM, Whitwell JL, Negash S, Ivnik RJ, Boeve BF, Knopman DS, Smith GE, Jack CR Jr (2008) Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 65, 1621-1628.
6. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M (2010) Memantine versus donepezil in mild to moderate Alzheimers disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17, 405-412.
7. Murray ME, Dickson DW, Jack CR, Kantarci K (2009) Aberrant tau pathology underlies H-1MRspectroscopic alterations in Alzheimers disease. Neurology 72, A173-A174.
8. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C (2009) Memantine in moderately-severe-to-severe Alzheimers disease: a postmarketing surveillance study. Drugs Aging 26, 321-332.
9. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5, 83-89. (Pubitemid 351536358)
10. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimers disease. Am J Psychiatry 141, 1356-1364.
11. Ashford JW, Kumar V, Barringer M, Becker M, Bice J, Ryan N,Vicari S (1992) Assessing Alzheimer severity with a global clinical scale. Int Psychogeriatr 4, 55-74.
12. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimers disease. Acta Neurol Scand Suppl 165, 3-12.
13. Jessen F, Gur O, Block W, Ende G, Frolich L, Hammen T, Wiltfang J, Kucinski T, Jahn H, Heun R, MaierW, Kolsch H, Kornhuber J, Traber F (2009) A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72, 1735-1740.
14. Ashford JW, Shan M, Butler S, Rajasekar A, Schmitt FA (1995) Temporal quantification of Alzheimers disease severity: time index model. Dementia 6, 269-280.
15. Westman E, Wahlund L-O, Foy C, Poppe M, Cooper A, Murphy D, Spenger C, Lovestone S, Simmons A (in press) Combining MRI and MRS to distinguish between Alzheimers disease and healthy controls. Journal of Alzheimers Disease
16. Kaufer D, Gandy S (2009) APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 73, 2052-2053.